{"ticker": {"uuid": "00f1b236-bdbe-483b-832e-6d89c220ece2", "symbol": "QNRX", "name": "Quoin Pharmaceuticals Ltd DRC", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 LS:A41BEM", "summary": "This article displays the cash flow from financing activities for Quoin Pharmaceuticals. Ltd Sponsored ADR (LS:A41BEM) on TradingView. It provides a placeholder for financial data (\"Period Value Change Change %\") related to this specific financial metric. The page is part of the ", "url": "https://www.tradingview.com/symbols/LS-A41BEM/financials-cash-flow/cash-f-financing-activities/", "source_name": "TradingView", "published_at": "2026-07-22T09:39:58", "published_display": "22 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Quoin Pharmaceuticals, Ltd. \u2013 NASDAQ:QNRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOTFFKeTNmSWp3SWRYajFwaWMxbFhhbXpMQ2NzX250eHlOZDhQLXpjZHlWUWU1ak1XTVlYemh1SlNBdW5zX0R4QnV2aV9PRnBPeHZXNGxwcFVPQ2VFd0NpR19mRS1nOXZTdjNZQXNyeGVRVm04YVdDeE42bzJFQ01KZ05TalJVRXotLWdZTi1RdV9jLXhFcFBadGtENlRpNEhPVWdLUUhxR1M0cU1W?oc=5", "source_name": "TradingView", "published_at": "2026-07-22T05:07:34+00:00", "published_display": "22 Jul 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Garners Buzz After FDA\u2019s Comments On Netherton Syndrome Lead Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYVQ1Zkt6eGNxM3RvN1A2bHo0SmRVVXppU0YxeGt6YkNhWEl3TkxOM2FRYXZFSlY3bXAzOUN6ZlVXOVh3S1p3MlIxdVBBUkdfUlB2U0l6T0hoa2g0SGdQRG1FWElvRndya2F3bFYwZDdkdldLeFZDWUc0RDYtWmY0SU1udUxYMHBaNHZrQWhubEU1a3lmSWNoUkdRc1pBRk5XWWRfUWVSOTcxMHBGdlJGbnpCNjNSblBLQnNSVDhtR2ItOEt3TS00dA?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-17T13:49:03+00:00", "published_display": "17 Jul 2026 13:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops", "summary": "Insiders at Quoin Pharmaceuticals, who collectively invested US$128.6k at an average price of US$8.49 per share over the last year, have seen their investment value drop to US$63.8k due to an 11% price decline. The biggest single purchase was by Independent Director Dennis Langer", "url": "https://www.sahmcapital.com/news/content/insider-traders-lose-us65k-as-quoin-pharmaceuticals-drops-2026-07-16", "source_name": "Sahm", "published_at": "2026-07-17T12:39:58", "published_display": "17 Jul 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals - Depositary Receipt (QNRX) price target increased by 12.66% to 30.26", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOeTVBOFZxWDZRbnZJelU4dlJxbC1wcE9UN3h3bjVGUVVUMUN6OW4wQ1BXbjNtQXphdTI1Qmg4UUNpMGhpc3NFbnVQUk01X2RzR3AzczV4XzltOUtYaTBxUUhfREJWQVhBZ09XV3UxcEhZcEliY0ZqUE51dVVMWUVNejZQRnp5U1BObVllcW1yOVZURjU0b0w2VHhNbkNjMXF4b3RlMVFjYUxlbjJWbVhjQ1lCN1V2N2c2MmxTWTJiZU11bnZGX0JUUVNLQmZnSWZ0?oc=5", "source_name": "MSN", "published_at": "2026-07-17T08:16:31+00:00", "published_display": "17 Jul 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 FWB:2EB0", "summary": "This page provides financial information for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is closed with no current trades. It also details tha", "url": "https://www.tradingview.com/symbols/FWB-2EB0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T23:40:13", "published_display": "16 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 FWB:2EB0", "summary": "This article displays the \"Enterprise value to EBIT forward\" for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades and provides a link to the financial data for the company. The rest of the c", "url": "https://www.tradingview.com/symbols/FWB-2EB0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T20:40:22", "published_display": "16 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Quoin Pharmaceuticals | ARS: Annual Report to Security Holders", "summary": "This article provides access to the Annual Report to Security Holders (ARS) for Quoin Pharmaceuticals. The report is a crucial document for investors and stakeholders, offering a comprehensive overview of the company's financial performance and operational activities over the pas", "url": "https://www.moomoo.com/news/notice/307726136/quoin-pharmaceuticals-ars-annual-report-to-security-holders", "source_name": "Moomoo", "published_at": "2026-07-16T19:11:14", "published_display": "16 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals (NASDAQ: QNRX) details 2026 meeting and pay votes", "summary": "Quoin Pharmaceuticals will hold its 2026 Annual General Meeting on August 20, 2026, where shareholders will vote on five key proposals, including the election of seven directors, an advisory \"say-on-pay\" for executive compensation, changes to director compensation, and changes to", "url": "https://www.stocktitan.net/sec-filings/QNRX/def-14a-quoin-pharmaceuticals-ltd-definitive-proxy-statement-e28e6a03c3be.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:11:14", "published_display": "16 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Maxim Group Maintains Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Maintains Target Price $16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNNVpqamJYTjdieHlKbEgtNXl0TkZVLXhWNVBnM0Zocjc0NmM5eHJNaGVVTjlobHNRSG5oRmJWMHhhYmtMYzBJSW5nZU1VSEdGVXRlRERkaDQxYmRVUkRvMThaOFQ5dTMtUjE3WGRiRll1SVZmTVllVVpRUXdNQWViWHh2bGhOdVJSVk9jYk0xMF96b0FnZkQ4S2psNUFCV1YzLS0zOUstTEFKdVFDcHdMZ0FTQ2tQWUFPRlE?oc=5", "source_name": "Moomoo", "published_at": "2026-07-11T12:31:00+00:00", "published_display": "11 Jul 2026 12:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome", "summary": "Quoin Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This marks the first formal clinical study for PSS, a", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324798/0/en/quoin-pharmaceuticals-receives-fda-ind-clearance-to-initiate-phase-2-study-of-qrx003-in-peeling-skin-syndrome.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T09:10:42", "published_display": "10 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals (QNRX) Gains FDA Approval for QRX003 Clinical Trial", "summary": "Quoin Pharmaceuticals (QNRX) has received FDA approval for its investigational new drug application for QRX003, intended to treat Peeling Skin Syndrome, enabling the company to proceed with Phase 2 clinical trials. The company, which focuses on rare diseases, has a strong financi", "url": "https://www.gurufocus.com/news/8951422/quoin-pharmaceuticals-qnrx-gains-fda-approval-for-qrx003-clinical-trial?mobile=true%3Fmobile%3Dtrue", "source_name": "GuruFocus", "published_at": "2026-07-09T20:10:42", "published_display": "09 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces FDA Clearance of QRX003 IND for Peeling Skin Syndrome, Plans Phase 2 Study in 2H 2026", "summary": "Quoin Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This will be the first formal clinical study for PSS, enr", "url": "https://www.quiverquant.com/news/Quoin+Pharmaceuticals+Announces+FDA+Clearance+of+QRX003+IND+for+Peeling+Skin+Syndrome,+Plans+Phase+2+Study+in+2H+2026", "source_name": "Quiver Quantitative", "published_at": "2026-07-09T12:44:00", "published_display": "09 Jul 2026 12:44", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare skin disease gets first company-backed clinical trial as Quoin wins FDA clearance", "summary": "Quoin Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome (PSS) in the second half of 2026. This marks the first IND cleared for PSS and the first company-sponsored formal cl", "url": "https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-receives-fda-ind-clearance-to-initiate-phase-2-pnct6vjcv1r3.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:21:22", "published_display": "09 Jul 2026 12:21", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form PRE 14A by Quoin Pharmaceuticals Ltd. for July 6th. The content is brief and primarily focuses on this regulatory filing, indicating an informational update rather than in-depth analysis.", "url": "https://uk.investing.com/news/stock-market-news/form-pre-14a-quoin-pharmaceuticals-ltd-for-6-july-93CH-4758601", "source_name": "Investing.com UK", "published_at": "2026-07-07T08:10:50", "published_display": "07 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition", "summary": "This document is a PRE 14A filing by Quoin Pharmaceuticals, indicating the submission of preliminary proxy statements related to a potential merger or acquisition. PRE 14A filings are used to notify shareholders of an upcoming vote on significant corporate actions, such as merger", "url": "https://www.moomoo.com/news/notice/307675275/quoin-pharmaceuticals-pre-14a-preliminary-proxy-statements-relating-to-merger", "source_name": "Moomoo", "published_at": "2026-07-07T03:11:55", "published_display": "07 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome", "summary": "Quoin Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome. This patent, which protects the company's investigational treatment QRX003, involves a topical serine p", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-receives-u-notice-123000281.html", "source_name": "Market source", "published_at": "2026-07-02T08:10:50", "published_display": "02 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QNRX - Quoin Pharmaceuticals Ltd ADR Volatility & Greeks", "summary": "This article provides a detailed financial overview of Quoin Pharmaceuticals Ltd ADR (QNRX), including its latest closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as volatility, RSI, beta, and histori", "url": "https://finviz.com/stock?t=QNRX&ty=ocv&ta=1&p=w", "source_name": "Finviz", "published_at": "2026-07-01T18:39:30", "published_display": "01 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Gets US Notice of Allowance for Netherton Syndrome Patent Application", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-gets-us-notice-131948386.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:19:48+00:00", "published_display": "30 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin wins U.S. patent step for Netherton syndrome treatment", "summary": "Quoin Pharmaceuticals (NASDAQ: QNRX) has received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, strengthening the intellectual property for its investigational topical therapy, QRX003 (QYLEKI). This patent covers a method using d", "url": "https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-receives-u-s-notice-of-allowance-for-patent-w4jol3z0em1y.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:54", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX)", "summary": "This page provides an overview of Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) including its stock market information, financial actuals, and analyst estimates. Users can explore reported financial data across income statements, balance sheets, and cash flow statements, comparing a", "url": "https://www.tradingview.com/symbols/NASDAQ-QNRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:34", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI\u2122 as the Proposed Brand Name for QRX003 for Netherton Syndrome", "summary": "Quoin Pharmaceuticals announced that the FDA has conditionally approved QYLEKI\u2122 as the proposed brand name for QRX003, its investigational product for Netherton Syndrome. This represents a significant milestone as the company moves towards potentially delivering the first approve", "url": "https://www.sahmcapital.com/news/content/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qyleki-as-the-proposed-brand-name-for-qrx003-for-netherton-syndrome-2026-06-23", "source_name": "Sahm", "published_at": "2026-06-24T15:40:38", "published_display": "24 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market", "summary": "Quoin Pharmaceuticals (QNRX) saw a significant post-market surge of 41.6% due to substantial insider buying activity. Several key insiders acquired over 1.7 million shares at an average price of $1.16 per share, indicating strong internal confidence in the company's future prospe", "url": "https://www.moomoo.com/news/post/71917454/trending-stocks-today-quoin-pharmaceuticals-shoots-up-41-6-post", "source_name": "Moomoo", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals: FDA Conditionally Accepts QYLEKI as Proposed Brand Name for QRX003", "summary": "Quoin Pharmaceuticals received conditional FDA acceptance for QYLEKI as the proposed brand name for QRX003, their treatment for Netherton Syndrome. This marks a significant regulatory step, with the company planning to seek final approval during the NDA process. QRX003 has multip", "url": "https://www.tradingview.com/news/tradingview:9db25dee7ddb3:0-quoin-pharmaceuticals-fda-conditionally-accepts-qyleki-as-proposed-brand-name-for-qrx003/", "source_name": "TradingView", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs QYLEKI name as Quoin (NASDAQ: QNRX) advances QRX003", "summary": "Quoin Pharmaceuticals announced that the FDA has conditionally approved QYLEKI\u2122 as the proposed brand name for QRX003, its investigational lotion for Netherton Syndrome. This product holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations, with a pivotal Phase 3 st", "url": "https://www.stocktitan.net/sec-filings/QNRX/8-k-quoin-pharmaceuticals-ltd-reports-material-event-81b8a3949b00.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market session, including both gainers and losers. Notable gainers include Quoin Pharmaceuticals (QNRX) and Mobile-health Network (MNDR), while Aditxt (ADTX) and Vivos Therapeutic", "url": "https://www.benzinga.com/trading-ideas/movers/26/06/60059568/12-health-care-stocks-moving-tuesday-s-after-market-session", "source_name": "Benzinga", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-apos-potential-skin-125837571.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:58:37+00:00", "published_display": "23 Jun 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA conditionally approves Quoin's QYLEKI name for rare skin drug", "summary": "Quoin Pharmaceuticals has received conditional FDA approval for QYLEKI as the proposed brand name for QRX003, their investigational treatment for Netherton Syndrome. This drug has multiple expedited designations and is on track for a pivotal Phase 3 study in late 2026, with a pot", "url": "https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qylekitm-caet2y5u2f0u.html", "source_name": "Stock Titan", "published_at": "2026-06-23T12:29:53", "published_display": "23 Jun 2026 12:29", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Ltd (QNRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article provides an analysis of Quoin Pharmaceuticals Ltd (QNRX)'s financial health, indicating a current financial score of 6.96, which ranks 180 out of 389 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating eff", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qnrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T09:11:53", "published_display": "23 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session - Quoin Pharmaceuticals (NASDAQ:QNRX), Mob", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVl9nMl9NMUtnTG9sbDA4ZDlGMlFZVUxkeFZldk0zWG91TG1WTEFxOUVWQ3REUmVlaEZBMEI5OXhubUxLbjlwZDRsR2lNT0lNUWpyQjB4dXVqWl81c1ZhdGJZUEFGcFVKTEZpOU5uYmVlM0V1aTJMSE52QjBvOWxYbWdJaVNIMUxkU0JXNUhVR2x0dVF2ZE9acU5oZjlXaUUwNVJDSDVKNHU0bnZVSEJhQ0otUHhvbFZzb2g1Wg?oc=5", "source_name": "Benzinga", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Ltd (QNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9DUzQwc1pTVEdNdS1GTURqZXlfTE1qOS0tcjA3cmdLY1I1RlM4TzR1VVl4MFJJeXZ1Y3RzVUp5V3prOGlrUjJiYUVIcWExXzIzMzNzR19BYWJfMGRCSV9aUkVHMDJaanJUMGZFbnFvUnE?oc=5", "source_name": "TradingKey", "published_at": "2026-06-19T02:58:28+00:00", "published_display": "19 Jun 2026 02:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-completes-establishment-japanese-123000924.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T12:30:00+00:00", "published_display": "18 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-announces-positive-clinical-123000399.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T12:30:00+00:00", "published_display": "16 Jun 2026 12:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quoin-pharmaceuticals-apos-skin-disorder-130321388.html", "source_name": "MT Newswires", "published_at": "2026-06-04T13:03:21+00:00", "published_display": "04 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quoin-pharmaceuticals-announces-japans-mhlw-123000424.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:30:00+00:00", "published_display": "04 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals stock rises on rare disease IND filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNU1DVlREX081WEFtRkVYMk9tWHpCcDBBN0EzZnZ6T1JhRVNnZUNCclVEaEprYm9zOFA0ZHlic3JEUXNqdHl2TlQyelY4dmY3cUw0WG05d2FtUnV6T3B0VHpCRlpjUHhsZDVZeVNjRU81R0JQTXk1bnBSVHRpa0ZXdzRiNjNlUzBuQ0stZi0zYmx6ekVEVlV5XzUwbkFHdG9zR1hnWlA1VVFmRUZfckFxTHVZLXBLNUhtcHpvTXIxWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Market Sentiment Around Loss-Making Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA opens door to a single late-stage trial for Quoin skin drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQcURWdk9yTUtNLTJIc3FiY1pQR3ptNDFtay0tRDdhY1k5c04xMTN5NnpvTG9vNDV1Y0ZfZlk3NFIzRnRfSzY1M2xadTVESGNSN1B6RFdGb3hXcDNlLXIzM2hDNm9fcmxtanlVN0oyckNVMWg3aF9ncnVqZ1Y1OHRCQ0lJcE9qMFRONWR5UXVJM3JlLUNVUDd6M2FKdXRLR2dzN096Z3BsdDlWOFZVaVRYWjVvZjNIMHhYN2s0MENR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPenZ1bWhEVlVsSW5CckhWNE54UlJaZ01YNHhva2RnMnZDVVhERDg3YzdWLXdDODRBazhQbGVzUzVDU29XdmZIdlRpRW5GcldkVUI0SnN3dnU4WFJKTGFvWlJETkdnZVhweVFnRFpyTEZuUVAzcERkX0ZuTzFfVEZLZU1xZUpGaTA0UWlCcTZSVC1lci1RRnkwdmhqbHVPWUx0aTdEbEZPRGVZQ3VCX1IzWnJrQXBoMk9xQi1NSm5FMDJNdlpTa1pYQnE3WHgtd0ZhSVBLM0FWRGJSRW5RRTlWMzhJdTNiMHNZUEE?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-10-10T07:00:00+00:00", "published_display": "10 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 LS:A41BEM", "summary": "This article displays the cash flow from financing activities for Quoin Pharmaceuticals. Ltd Sponsored ADR (LS:A41BEM) on TradingView. It provides a placeholder for financial data (\"Period Value Change Change %\") related to this specific financial metric. The page is part of the ", "url": "https://www.tradingview.com/symbols/LS-A41BEM/financials-cash-flow/cash-f-financing-activities/", "source_name": "TradingView", "published_at": "2026-07-22T09:39:58", "published_display": "22 Jul 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Quoin Pharmaceuticals, Ltd. \u2013 NASDAQ:QNRX", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOTFFKeTNmSWp3SWRYajFwaWMxbFhhbXpMQ2NzX250eHlOZDhQLXpjZHlWUWU1ak1XTVlYemh1SlNBdW5zX0R4QnV2aV9PRnBPeHZXNGxwcFVPQ2VFd0NpR19mRS1nOXZTdjNZQXNyeGVRVm04YVdDeE42bzJFQ01KZ05TalJVRXotLWdZTi1RdV9jLXhFcFBadGtENlRpNEhPVWdLUUhxR1M0cU1W?oc=5", "source_name": "TradingView", "published_at": "2026-07-22T05:07:34+00:00", "published_display": "22 Jul 2026 05:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Garners Buzz After FDA\u2019s Comments On Netherton Syndrome Lead Drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOYVQ1Zkt6eGNxM3RvN1A2bHo0SmRVVXppU0YxeGt6YkNhWEl3TkxOM2FRYXZFSlY3bXAzOUN6ZlVXOVh3S1p3MlIxdVBBUkdfUlB2U0l6T0hoa2g0SGdQRG1FWElvRndya2F3bFYwZDdkdldLeFZDWUc0RDYtWmY0SU1udUxYMHBaNHZrQWhubEU1a3lmSWNoUkdRc1pBRk5XWWRfUWVSOTcxMHBGdlJGbnpCNjNSblBLQnNSVDhtR2ItOEt3TS00dA?oc=5", "source_name": "Stocktwits", "published_at": "2026-07-17T13:49:03+00:00", "published_display": "17 Jul 2026 13:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Traders Lose US$65k As Quoin Pharmaceuticals Drops", "summary": "Insiders at Quoin Pharmaceuticals, who collectively invested US$128.6k at an average price of US$8.49 per share over the last year, have seen their investment value drop to US$63.8k due to an 11% price decline. The biggest single purchase was by Independent Director Dennis Langer", "url": "https://www.sahmcapital.com/news/content/insider-traders-lose-us65k-as-quoin-pharmaceuticals-drops-2026-07-16", "source_name": "Sahm", "published_at": "2026-07-17T12:39:58", "published_display": "17 Jul 2026 12:39", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals - Depositary Receipt (QNRX) price target increased by 12.66% to 30.26", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOeTVBOFZxWDZRbnZJelU4dlJxbC1wcE9UN3h3bjVGUVVUMUN6OW4wQ1BXbjNtQXphdTI1Qmg4UUNpMGhpc3NFbnVQUk01X2RzR3AzczV4XzltOUtYaTBxUUhfREJWQVhBZ09XV3UxcEhZcEliY0ZqUE51dVVMWUVNejZQRnp5U1BObVllcW1yOVZURjU0b0w2VHhNbkNjMXF4b3RlMVFjYUxlbjJWbVhjQ1lCN1V2N2c2MmxTWTJiZU11bnZGX0JUUVNLQmZnSWZ0?oc=5", "source_name": "MSN", "published_at": "2026-07-17T08:16:31+00:00", "published_display": "17 Jul 2026 08:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 FWB:2EB0", "summary": "This page provides financial information for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange, specifically focusing on its price to book forward metric. The content indicates that the market is closed with no current trades. It also details tha", "url": "https://www.tradingview.com/symbols/FWB-2EB0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T23:40:13", "published_display": "16 Jul 2026 23:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 FWB:2EB0", "summary": "This article displays the \"Enterprise value to EBIT forward\" for Quoin Pharmaceuticals. Ltd Sponsored ADR (FWB:2EB0) on the Frankfurt Stock Exchange. It indicates that the market is closed with no trades and provides a link to the financial data for the company. The rest of the c", "url": "https://www.tradingview.com/symbols/FWB-2EB0/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T20:40:22", "published_display": "16 Jul 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals | ARS: Annual Report to Security Holders", "summary": "This article provides access to the Annual Report to Security Holders (ARS) for Quoin Pharmaceuticals. The report is a crucial document for investors and stakeholders, offering a comprehensive overview of the company's financial performance and operational activities over the pas", "url": "https://www.moomoo.com/news/notice/307726136/quoin-pharmaceuticals-ars-annual-report-to-security-holders", "source_name": "Moomoo", "published_at": "2026-07-16T19:11:14", "published_display": "16 Jul 2026 19:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals (NASDAQ: QNRX) details 2026 meeting and pay votes", "summary": "Quoin Pharmaceuticals will hold its 2026 Annual General Meeting on August 20, 2026, where shareholders will vote on five key proposals, including the election of seven directors, an advisory \"say-on-pay\" for executive compensation, changes to director compensation, and changes to", "url": "https://www.stocktitan.net/sec-filings/QNRX/def-14a-quoin-pharmaceuticals-ltd-definitive-proxy-statement-e28e6a03c3be.html", "source_name": "Stock Titan", "published_at": "2026-07-16T11:11:14", "published_display": "16 Jul 2026 11:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Maxim Group Maintains Quoin Pharmaceuticals(QNRX.US) With Buy Rating, Maintains Target Price $16", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNNVpqamJYTjdieHlKbEgtNXl0TkZVLXhWNVBnM0Zocjc0NmM5eHJNaGVVTjlobHNRSG5oRmJWMHhhYmtMYzBJSW5nZU1VSEdGVXRlRERkaDQxYmRVUkRvMThaOFQ5dTMtUjE3WGRiRll1SVZmTVllVVpRUXdNQWViWHh2bGhOdVJSVk9jYk0xMF96b0FnZkQ4S2psNUFCV1YzLS0zOUstTEFKdVFDcHdMZ0FTQ2tQWUFPRlE?oc=5", "source_name": "Moomoo", "published_at": "2026-07-11T12:31:00+00:00", "published_display": "11 Jul 2026 12:31", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome", "summary": "Quoin Pharmaceuticals announced that the FDA has cleared its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This marks the first formal clinical study for PSS, a", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324798/0/en/quoin-pharmaceuticals-receives-fda-ind-clearance-to-initiate-phase-2-study-of-qrx003-in-peeling-skin-syndrome.html", "source_name": "GlobeNewswire", "published_at": "2026-07-10T09:10:42", "published_display": "10 Jul 2026 09:10", "sentiment": "positive", "sentiment_pct": 94, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals (QNRX) Gains FDA Approval for QRX003 Clinical Trial", "summary": "Quoin Pharmaceuticals (QNRX) has received FDA approval for its investigational new drug application for QRX003, intended to treat Peeling Skin Syndrome, enabling the company to proceed with Phase 2 clinical trials. The company, which focuses on rare diseases, has a strong financi", "url": "https://www.gurufocus.com/news/8951422/quoin-pharmaceuticals-qnrx-gains-fda-approval-for-qrx003-clinical-trial?mobile=true%3Fmobile%3Dtrue", "source_name": "GuruFocus", "published_at": "2026-07-09T20:10:42", "published_display": "09 Jul 2026 20:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces FDA Clearance of QRX003 IND for Peeling Skin Syndrome, Plans Phase 2 Study in 2H 2026", "summary": "Quoin Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application for QRX003 to treat Peeling Skin Syndrome (PSS), allowing a Phase 2 clinical study to commence in the second half of 2026. This will be the first formal clinical study for PSS, enr", "url": "https://www.quiverquant.com/news/Quoin+Pharmaceuticals+Announces+FDA+Clearance+of+QRX003+IND+for+Peeling+Skin+Syndrome,+Plans+Phase+2+Study+in+2H+2026", "source_name": "Quiver Quantitative", "published_at": "2026-07-09T12:44:00", "published_display": "09 Jul 2026 12:44", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Rare skin disease gets first company-backed clinical trial as Quoin wins FDA clearance", "summary": "Quoin Pharmaceuticals has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 2 study of QRX003 for Peeling Skin Syndrome (PSS) in the second half of 2026. This marks the first IND cleared for PSS and the first company-sponsored formal cl", "url": "https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-receives-fda-ind-clearance-to-initiate-phase-2-pnct6vjcv1r3.html", "source_name": "Stock Titan", "published_at": "2026-07-09T12:21:22", "published_display": "09 Jul 2026 12:21", "sentiment": "positive", "sentiment_pct": 81, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form PRE 14A Quoin Pharmaceuticals Ltd. For: 6 July By Investing.com", "summary": "This article from Investing.com announces the filing of Form PRE 14A by Quoin Pharmaceuticals Ltd. for July 6th. The content is brief and primarily focuses on this regulatory filing, indicating an informational update rather than in-depth analysis.", "url": "https://uk.investing.com/news/stock-market-news/form-pre-14a-quoin-pharmaceuticals-ltd-for-6-july-93CH-4758601", "source_name": "Investing.com UK", "published_at": "2026-07-07T08:10:50", "published_display": "07 Jul 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition", "summary": "This document is a PRE 14A filing by Quoin Pharmaceuticals, indicating the submission of preliminary proxy statements related to a potential merger or acquisition. PRE 14A filings are used to notify shareholders of an upcoming vote on significant corporate actions, such as merger", "url": "https://www.moomoo.com/news/notice/307675275/quoin-pharmaceuticals-pre-14a-preliminary-proxy-statements-relating-to-merger", "source_name": "Moomoo", "published_at": "2026-07-07T03:11:55", "published_display": "07 Jul 2026 03:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Receives U.S. Notice of Allowance for Patent Covering Combination Treatment for Netherton Syndrome", "summary": "Quoin Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome. This patent, which protects the company's investigational treatment QRX003, involves a topical serine p", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-receives-u-notice-123000281.html", "source_name": "Market source", "published_at": "2026-07-02T08:10:50", "published_display": "02 Jul 2026 08:10", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "QNRX - Quoin Pharmaceuticals Ltd ADR Volatility & Greeks", "summary": "This article provides a detailed financial overview of Quoin Pharmaceuticals Ltd ADR (QNRX), including its latest closing price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as volatility, RSI, beta, and histori", "url": "https://finviz.com/stock?t=QNRX&ty=ocv&ta=1&p=w", "source_name": "Finviz", "published_at": "2026-07-01T18:39:30", "published_display": "01 Jul 2026 18:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Gets US Notice of Allowance for Netherton Syndrome Patent Application", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-gets-us-notice-131948386.html", "source_name": "MT Newswires", "published_at": "2026-06-30T13:19:48+00:00", "published_display": "30 Jun 2026 13:19", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin wins U.S. patent step for Netherton syndrome treatment", "summary": "Quoin Pharmaceuticals (NASDAQ: QNRX) has received a U.S. Notice of Allowance for a patent covering a combination treatment for Netherton Syndrome, strengthening the intellectual property for its investigational topical therapy, QRX003 (QYLEKI). This patent covers a method using d", "url": "https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-receives-u-s-notice-of-allowance-for-patent-w4jol3z0em1y.html", "source_name": "Stock Titan", "published_at": "2026-06-30T12:39:54", "published_display": "30 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals. Ltd Sponsored ADR Actuals & Estimates (NASDAQ:QNRX)", "summary": "This page provides an overview of Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX) including its stock market information, financial actuals, and analyst estimates. Users can explore reported financial data across income statements, balance sheets, and cash flow statements, comparing a", "url": "https://www.tradingview.com/symbols/NASDAQ-QNRX/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T09:39:34", "published_display": "26 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKI\u2122 as the Proposed Brand Name for QRX003 for Netherton Syndrome", "summary": "Quoin Pharmaceuticals announced that the FDA has conditionally approved QYLEKI\u2122 as the proposed brand name for QRX003, its investigational product for Netherton Syndrome. This represents a significant milestone as the company moves towards potentially delivering the first approve", "url": "https://www.sahmcapital.com/news/content/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qyleki-as-the-proposed-brand-name-for-qrx003-for-netherton-syndrome-2026-06-23", "source_name": "Sahm", "published_at": "2026-06-24T15:40:38", "published_display": "24 Jun 2026 15:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Trending Stocks Today | Quoin Pharmaceuticals Shoots up 41.6% Post-Market", "summary": "Quoin Pharmaceuticals (QNRX) saw a significant post-market surge of 41.6% due to substantial insider buying activity. Several key insiders acquired over 1.7 million shares at an average price of $1.16 per share, indicating strong internal confidence in the company's future prospe", "url": "https://www.moomoo.com/news/post/71917454/trending-stocks-today-quoin-pharmaceuticals-shoots-up-41-6-post", "source_name": "Moomoo", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 81, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals: FDA Conditionally Accepts QYLEKI as Proposed Brand Name for QRX003", "summary": "Quoin Pharmaceuticals received conditional FDA acceptance for QYLEKI as the proposed brand name for QRX003, their treatment for Netherton Syndrome. This marks a significant regulatory step, with the company planning to seek final approval during the NDA process. QRX003 has multip", "url": "https://www.tradingview.com/news/tradingview:9db25dee7ddb3:0-quoin-pharmaceuticals-fda-conditionally-accepts-qyleki-as-proposed-brand-name-for-qrx003/", "source_name": "TradingView", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 80, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA backs QYLEKI name as Quoin (NASDAQ: QNRX) advances QRX003", "summary": "Quoin Pharmaceuticals announced that the FDA has conditionally approved QYLEKI\u2122 as the proposed brand name for QRX003, its investigational lotion for Netherton Syndrome. This product holds Orphan Drug, Fast Track, and Rare Pediatric Disease designations, with a pivotal Phase 3 st", "url": "https://www.stocktitan.net/sec-filings/QNRX/8-k-quoin-pharmaceuticals-ltd-reports-material-event-81b8a3949b00.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session", "summary": "This article lists 12 healthcare stocks that experienced significant movement during Tuesday's after-market session, including both gainers and losers. Notable gainers include Quoin Pharmaceuticals (QNRX) and Mobile-health Network (MNDR), while Aditxt (ADTX) and Vivos Therapeutic", "url": "https://www.benzinga.com/trading-ideas/movers/26/06/60059568/12-health-care-stocks-moving-tuesday-s-after-market-session", "source_name": "Benzinga", "published_at": "2026-06-23T20:39:46", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals' Potential Skin Disease Treatment Receives US Name Approval", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-apos-potential-skin-125837571.html", "source_name": "MT Newswires", "published_at": "2026-06-23T12:58:37+00:00", "published_display": "23 Jun 2026 12:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA conditionally approves Quoin's QYLEKI name for rare skin drug", "summary": "Quoin Pharmaceuticals has received conditional FDA approval for QYLEKI as the proposed brand name for QRX003, their investigational treatment for Netherton Syndrome. This drug has multiple expedited designations and is on track for a pivotal Phase 3 study in late 2026, with a pot", "url": "https://www.stocktitan.net/news/QNRX/quoin-pharmaceuticals-receives-fda-conditional-approval-of-qylekitm-caet2y5u2f0u.html", "source_name": "Stock Titan", "published_at": "2026-06-23T12:29:53", "published_display": "23 Jun 2026 12:29", "sentiment": "positive", "sentiment_pct": 72, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Ltd (QNRX) Financial Health: Profitability & Balance Sheet Analysis", "summary": "The article provides an analysis of Quoin Pharmaceuticals Ltd (QNRX)'s financial health, indicating a current financial score of 6.96, which ranks 180 out of 389 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating eff", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-qnrx/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T09:11:53", "published_display": "23 Jun 2026 09:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "12 Health Care Stocks Moving In Tuesday's After-Market Session - Quoin Pharmaceuticals (NASDAQ:QNRX), Mob", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxQVl9nMl9NMUtnTG9sbDA4ZDlGMlFZVUxkeFZldk0zWG91TG1WTEFxOUVWQ3REUmVlaEZBMEI5OXhubUxLbjlwZDRsR2lNT0lNUWpyQjB4dXVqWl81c1ZhdGJZUEFGcFVKTEZpOU5uYmVlM0V1aTJMSE52QjBvOWxYbWdJaVNIMUxkU0JXNUhVR2x0dVF2ZE9acU5oZjlXaUUwNVJDSDVKNHU0bnZVSEJhQ0otUHhvbFZzb2g1Wg?oc=5", "source_name": "Benzinga", "published_at": "2026-06-23T07:00:00+00:00", "published_display": "23 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Ltd (QNRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "", "url": "https://news.google.com/rss/articles/CBMicEFVX3lxTE9DUzQwc1pTVEdNdS1GTURqZXlfTE1qOS0tcjA3cmdLY1I1RlM4TzR1VVl4MFJJeXZ1Y3RzVUp5V3prOGlrUjJiYUVIcWExXzIzMzNzR19BYWJfMGRCSV9aUkVHMDJaanJUMGZFbnFvUnE?oc=5", "source_name": "TradingKey", "published_at": "2026-06-19T02:58:28+00:00", "published_display": "19 Jun 2026 02:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-completes-establishment-japanese-123000924.html", "source_name": "GlobeNewswire", "published_at": "2026-06-18T12:30:00+00:00", "published_display": "18 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/quoin-pharmaceuticals-announces-positive-clinical-123000399.html", "source_name": "GlobeNewswire", "published_at": "2026-06-16T12:30:00+00:00", "published_display": "16 Jun 2026 12:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals' Skin Disorder Drug Receives Orphan Drug Designation in Japan", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quoin-pharmaceuticals-apos-skin-disorder-130321388.html", "source_name": "MT Newswires", "published_at": "2026-06-04T13:03:21+00:00", "published_display": "04 Jun 2026 13:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/quoin-pharmaceuticals-announces-japans-mhlw-123000424.html", "source_name": "GlobeNewswire", "published_at": "2026-06-04T12:30:00+00:00", "published_display": "04 Jun 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals stock rises on rare disease IND filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNNU1DVlREX081WEFtRkVYMk9tWHpCcDBBN0EzZnZ6T1JhRVNnZUNCclVEaEprYm9zOFA0ZHlic3JEUXNqdHl2TlQyelY4dmY3cUw0WG05d2FtUnV6T3B0VHpCRlpjUHhsZDVZeVNjRU81R0JQTXk1bnBSVHRpa0ZXdzRiNjNlUzBuQ0stZi0zYmx6ekVEVlV5XzUwbkFHdG9zR1hnWlA1VVFmRUZfckFxTHVZLXBLNUhtcHpvTXIxWQ?oc=5", "source_name": "Investing.com", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Market Sentiment Around Loss-Making Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX)", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "FDA opens door to a single late-stage trial for Quoin skin drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQcURWdk9yTUtNLTJIc3FiY1pQR3ptNDFtay0tRDdhY1k5c04xMTN5NnpvTG9vNDV1Y0ZfZlk3NFIzRnRfSzY1M2xadTVESGNSN1B6RFdGb3hXcDNlLXIzM2hDNm9fcmxtanlVN0oyckNVMWg3aF9ncnVqZ1Y1OHRCQ0lJcE9qMFRONWR5UXVJM3JlLUNVUDd6M2FKdXRLR2dzN096Z3BsdDlWOFZVaVRYWjVvZjNIMHhYN2s0MENR?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Quoin Pharmaceuticals Announces Private Placement Financing of Up to $104.5 Million", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxPenZ1bWhEVlVsSW5CckhWNE54UlJaZ01YNHhva2RnMnZDVVhERDg3YzdWLXdDODRBazhQbGVzUzVDU29XdmZIdlRpRW5GcldkVUI0SnN3dnU4WFJKTGFvWlJETkdnZVhweVFnRFpyTEZuUVAzcERkX0ZuTzFfVEZLZU1xZUpGaTA0UWlCcTZSVC1lci1RRnkwdmhqbHVPWUx0aTdEbEZPRGVZQ3VCX1IzWnJrQXBoMk9xQi1NSm5FMDJNdlpTa1pYQnE3WHgtd0ZhSVBLM0FWRGJSRW5RRTlWMzhJdTNiMHNZUEE?oc=5", "source_name": "GlobeNewswire", "published_at": "2025-10-10T07:00:00+00:00", "published_display": "10 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 86, "total_relevant": 48, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 32, "score": 58, "total": 48, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 11.55, "count": 21}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 6.6, "count": 12}, {"event": "earnings", "label": "Earnings", "weight": 4.26, "count": 10}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 4.24, "latest_week": "2026-07-17", "one_week_move": -4.7, "four_week_move": -8.8, "twelve_week_move": -25.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.338666, "market_dynamics_buy_signal": false, "relative_strength": -57.337404, "fair_value_gap": -90.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 37.3487, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-4.7% over one week, -8.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 66, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingView", "count": 7}, {"label": "Market source", "count": 7}, {"label": "Stock Titan", "count": 6}, {"label": "GlobeNewswire", "count": 5}, {"label": "Moomoo", "count": 4}, {"label": "MT Newswires", "count": 3}, {"label": "simplywall.st", "count": 3}, {"label": "Sahm", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 39}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 21}, {"label": "Regulatory and legal", "count": 12}, {"label": "Earnings", "count": 10}, {"label": "Analyst action", "count": 3}, {"label": "Balance sheet", "count": 1}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "39", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-4.7% over one week, -8.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Cash flow from financing activities of Quoin Pharmaceuticals. Ltd Sponsored ADR \u2013 LS:A41BEM"}], "updated_at": "2026-07-23T01:58:49.956351+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}